Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax (2021 - 2025)

Ironwood Pharmaceuticals' Long-Term Deferred Tax history spans 5 years, with the latest figure at $101.7 million for Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax fell 45.13% year-over-year to $101.7 million; the TTM value through Sep 2025 reached $101.7 million, down 45.13%, while the annual FY2024 figure was $144.2 million, 32.07% down from the prior year.
  • Long-Term Deferred Tax for Q3 2025 was $101.7 million at Ironwood Pharmaceuticals, down from $129.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $337.8 million in Q2 2021 and bottomed at $101.7 million in Q3 2025.
  • The 5-year median for Long-Term Deferred Tax is $250.8 million (2023), against an average of $240.9 million.
  • The largest annual shift saw Long-Term Deferred Tax dropped 5.11% in 2022 before it tumbled 45.13% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $333.3 million in 2021, then fell by 14.89% to $283.7 million in 2022, then decreased by 25.15% to $212.3 million in 2023, then crashed by 32.07% to $144.2 million in 2024, then dropped by 29.5% to $101.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Long-Term Deferred Tax are $101.7 million (Q3 2025), $129.5 million (Q2 2025), and $143.6 million (Q1 2025).